Skip to main content

An evaluation of the therapeutic value, benefits and risks of methylenedioxymethamphetamine (MDMA) and psilocybin for the treatment of mental, behavioural or developmental disorders

Summary of a report to the Therapeutic Goods Administration.
Last updated

Help us improve this page

This form is anonymous. If you would like a response from us, please visit Contact us.